Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsReiterationPrice Target
Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform and maintains $17 price target.
Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform and maintains $17 price target.